Patient characteristics and treatment outcomes in the validation part 2.

This table presents the demographic and clinical characteristics of patients included in the validation part 2 of the study on immune checkpoint inhibitors (ICIs). The parameters are as follows: ICIs (type of immune checkpoint inhibitor), Sex (Male, Female), Age, RDW (Red Cell Distribution Width), Target (classification into Early-discontinuation group), and Number of ICIs doses (N of ICIs doses).
(XLSX)